Acute Myeloid Leukemia (AML) by FAB Classification

FAB classification (Types)
Causes and risk factors
Symptoms and signs
Diagnostic tests
Non-Pharmacological Treatments
Drug Treatments
Dietary “Molecular” Supports
Immunity/Regenerative/Stem-Cell–Related” Medicines
Common Procedures/“Surgeries
Prevention & Safety Tips
When to See (or Call) Your Doctor Urgently
What to Eat and What to Avoid
Frequently Asked Questions

Acute myeloid leukemia is a fast-growing cancer of the bone marrow. The marrow makes too many abnormal myeloid “blast” cells. These blasts crowd out normal blood-forming cells. As a result, the body has low red cells, low platelets, and poorly working white cells. Infections, bleeding, and severe tiredness can happen quickly. Doctors diagnose AML by blood tests, bone-marrow tests, and special markers on the leukemia cells.

Acute myeloid leukemia (AML) is a fast-growing blood and bone-marrow cancer where immature myeloid cells (“blasts”) build up and crowd out normal blood cells. The French-American-British (FAB) system is a practical, older way to sort AML into eight subtypes (M0–M7) based on how the leukemia cells look under the microscope and which cell line they resemble.

M0 undifferentiated; M1 minimal maturation; M2 with maturation; M3 acute promyelocytic leukemia (APL); M4 myelomonocytic; M5 monocytic; M6 erythroid/erythroblastic; M7 megakaryocytic. Today, doctors also use modern genetic-based classifications (WHO/ICC), but FAB is still helpful for basic understanding and historical studies. NCBIMedscapeAmerican Cancer Society

Subtypes point to different behaviors, risks, and treatment paths. One standout: APL (FAB-M3) behaves uniquely and is usually treated with ATRA (all-trans retinoic acid) and arsenic trioxide (ATO) rather than standard chemotherapy, because these drugs mature the blasts instead of just killing them. This approach achieves very high cure rates in many patients. New England Journal of MedicineMedscapeAmerican Cancer Society

Other names

Acute myelogenous leukemia; acute myelocytic leukemia; acute myeloblastic leukemia; acute non-lymphocytic leukemia (ANLL); myeloid acute leukemia; granulocytic leukemia. Subtype-specific names include acute promyelocytic leukemia (APL; FAB-M3), acute myelomonocytic leukemia (M4), acute monocytic leukemia (M5), erythroid leukemia (M6), and megakaryoblastic leukemia (M7).

FAB classification (Types)

The French–American–British (FAB) system classifies AML by how the leukemia cells look and mature under the microscope, and by a few simple stains. It uses codes M0 through M7.

M0 — Minimally differentiated AML

Blasts show myeloid origin only on special immunologic tests, not on routine stains. Cells look very immature. Symptoms are typical of AML: infections, bleeding, fatigue. Diagnosis rests on flow cytometry and molecular tests because classic stains are often negative.

M1 — AML without maturation

Most marrow cells are myeloblasts with little maturation into later myeloid forms. Myeloperoxidase or Sudan Black B stains are usually positive. Patients present with severe cytopenias. Treatment is standard AML induction unless molecular markers suggest a special approach.

M2 — AML with maturation

There are many myeloblasts and more mature neutrophil precursors. t(8;21) may be seen in some cases and often predicts better response to standard therapy. Gum swelling and tissue infiltration are less common than in monocytic types.

M3 — Acute promyelocytic leukemia (APL)

Leukemia cells are abnormal promyelocytes packed with granules and Auer rods. A unique gene fusion, usually PML::RARA, blocks maturation. Patients are at high risk of life-threatening clotting and bleeding (DIC). Treatment is urgent with all-trans retinoic acid (ATRA) and arsenic trioxide, which can cure many patients by forcing the cells to mature.

M3 variant (microgranular APL)

Cells have fewer visible granules but behave like APL. White-cell counts may be high. The same life-threatening DIC risk and the same targeted treatment with ATRA/arsenic apply.

M4 — Acute myelomonocytic leukemia

Leukemia shows both myeloid and monocytic features. Patients may have swollen gums, skin lesions (leukemia cutis), and enlarged spleen or liver due to tissue infiltration. A special subtype, M4-eo, includes increased eosinophils and often has core-binding factor abnormalities with favorable risk.

M4-eo — AML with eosinophilia

A subset of M4 with many abnormal eosinophils and characteristic chromosome changes (e.g., inv(16) or t(16;16)). Often responds well to standard chemotherapy.

M5 — Acute monocytic/monoblastic leukemia

Two patterns: M5a (mostly monoblasts) and M5b (more mature monocytes). Gum hypertrophy, skin nodules, and CNS involvement are more common. Blood clotting can be abnormal. Tumor lysis can occur at diagnosis or during therapy.

M6 — Erythroid leukemia

Abnormal growth of immature red-cell precursors. Patients may show severe anemia with very abnormal red-cell forms in the marrow. This category is rare and now defined more strictly in modern systems, but in FAB it included marked erythroid proliferation.

M7 — Acute megakaryoblastic leukemia

Leukemia of platelet-forming cells (megakaryoblasts). Fibrosis of the marrow is common, so aspiration may be “dry,” and biopsy is needed. It can present in infants and is associated with Down syndrome in a special, more treatment-responsive form.

Important note. Today, most centers also use the WHO/ICC risk-based systems that add cytogenetic and molecular features to guide therapy. FAB is still useful for quick morphologic description and historical context.

Causes and risk factors

AML rarely has a single “cause.” It usually results from several genetic hits plus environmental or treatment exposures. Below are well-supported risk factors that raise the chance of AML.

Older age: DNA damage accumulates over time, and bone-marrow stem cells become more vulnerable to malignant change.
Prior chemotherapy (alkylating agents): Drugs like cyclophosphamide can injure stem-cell DNA; AML may arise years later.
Prior chemotherapy (topoisomerase II inhibitors): Agents like etoposide can create specific gene breaks; AML may appear within 1–3 years.
Radiation therapy or high environmental radiation: Ionizing radiation mutates DNA in marrow cells.
Benzene exposure: This industrial solvent damages marrow stem cells; chronic exposure increases AML risk.
Cigarette smoking: Tobacco contains benzene and other carcinogens that reach the marrow through the blood.
Myelodysplastic syndromes (MDS): Pre-leukemic disorders can transform into AML as new mutations accumulate.
Myeloproliferative neoplasms (e.g., polycythemia vera, myelofibrosis): These chronic diseases can evolve into secondary AML.
Clonal hematopoiesis (CHIP/CCUS): Age-related clones with mutations like DNMT3A, TET2, or ASXL1 increase future AML risk.
Family history of AML or germline syndromes: Inherited mutations (RUNX1, CEBPA, DDX41, GATA2) predispose to AML.
Down syndrome (Trisomy 21): Especially linked to transient abnormal myelopoiesis and megakaryoblastic AML in infants/children.
Fanconi anemia: A DNA-repair disorder causing marrow failure and high leukemia risk.
Bloom, Ataxia-telangiectasia, and other DNA-repair syndromes: Reduced DNA repair allows malignant clones to emerge.
Neurofibromatosis type 1: RAS-pathway dysregulation can increase myeloid malignancy risk in children.
Noonan syndrome: Germline RAS-pathway mutations can predispose to myeloproliferation and AML.
Aplastic anemia (treated or untreated): Damaged marrow and prior immunosuppressive therapy can be followed by AML in a minority.
Long-term pesticide/petrochemical exposure: Some occupational exposures correlate with higher AML incidence.
Obesity: Chronic inflammation and altered hormones may promote clonal evolution in marrow.
Prior organ transplant with chronic immunosuppression: Long-term DNA stress and impaired immune surveillance can contribute.
Male sex and certain ethnic backgrounds (population-level association): Small risk differences exist, likely from environmental and genetic factors combined.

Symptoms and signs

Symptoms come from low normal blood cells, high leukemia burden, or organ infiltration. They often develop over days to weeks.

Severe tiredness and weakness from anemia.
Shortness of breath on exertion because the blood carries less oxygen.
Pale skin and inside of eyelids due to low red cells.
Frequent infections or fevers because white cells are abnormal and cannot fight germs.
Mouth ulcers, sore throat, or gum swelling (especially in monocytic types).
Easy bruising and purple spots (petechiae) from low platelets.
Frequent nosebleeds or bleeding gums that are hard to stop.
Prolonged bleeding from small cuts because clotting is weak.
Bone pain or tenderness from an overfull marrow.
Fullness in the left upper belly from an enlarged spleen; sometimes the liver is enlarged too.
Unintended weight loss and night sweats from high cell turnover and inflammation.
Skin nodules or rashes (leukemia cutis) in myelomonocytic/monocytic subtypes.
Headache, confusion, or vision problems if blasts enter the brain or if the white-cell count is extremely high.
Signs of clotting/bleeding crisis in APL (M3): nosebleeds, oozing at lines, bruising, low fibrinogen.
Swollen lymph nodes (less common than in lymphoid leukemias, but can appear in monocytic types).

Diagnostic tests

A) Physical examination

General assessment and vital signs: Temperature, pulse, breathing, and blood pressure show infection, anemia stress, or shock. A very ill appearance or sepsis requires urgent action.
Skin and mucosa inspection: Pallor, petechiae, ecchymoses, and mouth ulcers point to anemia and thrombocytopenia. Rashes or nodules may suggest leukemia cutis.
Oral and gum exam: Gum hypertrophy and bleeding are classic in M4/M5; ulcers reflect neutropenia.
Abdominal palpation: Enlarged spleen or liver suggests heavy disease burden or a myelomonocytic/monocytic subtype.
Lymph-node and bone tenderness check: Firm nodes are less typical but possible; sternal tenderness hints at overactive, crowded marrow.

B) “Manual” bedside tests and clinical maneuvers

Capillary refill time: Slow refill (>2 seconds) may signal poor perfusion from anemia or sepsis.
Orthostatic blood pressure/heart-rate testing: Dizziness and drops in pressure can reflect anemia, dehydration, or sepsis.
Manual differential review at the microscope: A laboratorian or hematologist visually reviews the blood smear to confirm blasts, Auer rods, and dysplasia beyond the automated counter.
Cytochemical stains (MPO, Sudan Black B, non-specific esterase, PAS): Simple, manual stains help separate myeloid from monocytic or lymphoid blasts and historically define FAB types.

C) Laboratory and pathological studies

Complete blood count (CBC) with automated differential: Often shows anemia, thrombocytopenia, and high or low white-cell counts; blasts may appear in peripheral blood.
Peripheral blood smear (morphology): Confirms blasts, Auer rods, hypogranulation, pseudo-Pelger cells, or monocytic forms; guides urgent care.
Bone-marrow aspiration and biopsy: Gold standard. Shows ≥20% blasts in most AML (except APL defined by genetics). Biopsy assesses cellularity and fibrosis (important for M7).
Flow-cytometry immunophenotyping: Detects cell-surface and cytoplasmic markers (e.g., CD34, CD117, MPO, CD13, CD33, CD64, HLA-DR) to assign lineage, confirm AML, and identify APL patterns (e.g., bright CD33, absent HLA-DR).
Conventional cytogenetics (karyotype): Finds chromosome gains, losses, and translocations (e.g., t(8;21), inv(16), t(15;17), complex karyotype). These changes are critical for prognosis and therapy.
FISH and targeted molecular testing: Detects key fusions (PML::RARA in APL), FLT3-ITD/TKD, NPM1, CEBPA, IDH1/2, RUNX1, TP53, KIT, and others. Results stratify risk and guide targeted drugs.
Coagulation profile (PT/INR, aPTT, fibrinogen, D-dimer): Screens for DIC, especially in APL. Low fibrinogen and high D-dimer require immediate correction while APL therapy starts.
Chemistry/tumor-lysis labs (uric acid, LDH, potassium, phosphate, calcium, creatinine, liver enzymes): Evaluate disease burden, organ function, and risk of tumor lysis before and during treatment.

D) Electrodiagnostic test

12-lead ECG: Checks rhythm, conduction, and QT interval. It is important at baseline and during therapy (electrolyte shifts, sepsis, and some drugs can provoke arrhythmias or QT prolongation).

E) Imaging studies

Chest X-ray: Looks for pneumonia (neutropenia risk), line complications, or rarely mediastinal widening. It supports urgent infection care.
Echocardiography (or cardiac ultrasound): Baseline heart function (LVEF) before anthracyclines/arsenic; helps choose and dose therapy safely. Abdominal ultrasound or CT may also be used when organ enlargement or tissue infiltration is suspected.

Non-Pharmacological Treatments

All items are safe-language supportive measures used with medical care. They don’t cure AML but help you tolerate therapy, move safely, and recover function. Always clear activity with your oncology team—plans change with counts, fever, or procedures.

A) Physiotherapy-Focused Interventions

Energy-conserving daily-activity training
What/why: Learn pacing, planning, and rest-breaks to get through hygiene, meals, and short walks without crashing.
Mechanism: Reduces oxygen demand and lactate build-up; avoids post-exertional fatigue when hemoglobin is low.
Benefits: Better independence, fewer near-falls, and steadier progress between chemo cycles.
Bed mobility and transfer practice
What/why: Step-by-step techniques to turn in bed, sit up, and transfer to a chair/wheelchair safely.
Mechanism: Builds core/hip activation while respecting lines/ports and platelet limits.
Benefits: Less deconditioning, pressure-injury prevention, and safer toileting.
Gentle range-of-motion (ROM) for all limbs
What/why: Daily shoulder/hip/knee/ankle ROM.
Mechanism: Lubricates joints, maintains muscle length during bed rest.
Benefits: Fewer contractures and less stiffness when you resume walking.
Low-intensity resistance with bands (when counts allow)
What/why: 1–2 sets, very light resistance, major muscle groups.
Mechanism: Signals muscle protein synthesis; slows sarcopenia from steroids or inactivity.
Benefits: Keeps strength for transfers and stair steps.
Posture and breathing drills
What/why: Diaphragmatic breathing, thoracic mobility, and gentle inspiratory muscle work.
Mechanism: Improves ventilation and cough effectiveness; reduces atelectasis risk.
Benefits: Easier breathing during anemia or after sedation.
Gait re-training with assistive devices
What/why: Walker or cane fitting; hallway “lap” goals.
Mechanism: Stabilizes COM (center of mass); lowers fall risk if platelets are low.
Benefits: Safer, longer walks with confidence.
Balance and proprioception (static → dynamic)
What/why: Feet-together stance, semi-tandem, single-leg holds as safe.
Mechanism: Cerebellar and ankle-strategy tuning; vestibular reinforcement.
Benefits: Fewer stumbles, smoother transfers.
Orthostatic intolerance management
What/why: Head-of-bed elevation, ankle pumps, slow positional changes.
Mechanism: Venous return support and autonomic adaptation.
Benefits: Less dizziness and fainting.
Peripheral neuropathy self-care training
What/why: Foot checks, wide-toe shoes, hazard scanning.
Mechanism: Compensates for sensory loss from certain drugs.
Benefits: Fewer skin injuries and trips.
Pelvic-floor and core stability
What/why: Gentle bracing, breath-coupled pelvic-floor lifts.
Mechanism: Improves intra-abdominal pressure control for cough and transfers.
Benefits: Less back strain, improved continence.
Shoulder/scapular care around central lines
What/why: Pain-free shoulder elevation and scapular glides.
Mechanism: Preserves overhead reach without line tension.
Benefits: Prevents “frozen shoulder.”
Respiratory hygiene & incentive spirometry (as ordered)
What/why: Cueing for regular use when sedated or lying down more.
Mechanism: Recruits alveoli and clears mucus.
Benefits: Lowers pneumonia risk.
Edema management and gentle calf pumps
What/why: Elevation, ankle circles, walking bursts.
Mechanism: Improves venous/lymph return.
Benefits: Lighter legs, better fit in shoes.
Safe-body mechanics for caregivers and patients
What/why: How to roll, pivot, and lift safely.
Mechanism: Keeps neutral spine and joint protection.
Benefits: Fewer musculoskeletal injuries at home.
Home exercise plan with “stop rules”
What/why: Simple, count-aware plan with thresholds to stop (fever, bleeding, chest pain).
Mechanism: Autonomy plus guardrails.
Benefits: Keeps progress steady and safe.

B) Mind-Body & Educational Therapies (non-drug)

Fatigue education + activity diaries – Understand anemia-related fatigue vs. “overdoing,” set SMART goals; reduces boom-and-bust cycles.
Sleep hygiene coaching – Light cues, regular wake time, limit late naps; improves energy and immune function signals.
Guided relaxation or mindfulness – Brief daily practice reduces sympathetic overdrive, may lower pain perception and anxiety.
Breath-to-movement yoga (chair/bed-adapted) – Very gentle sequences; supports flexibility and calm without strain.
Cognitive-behavioral coping skills – Reframe worries, plan around uncertainty; improves adherence and mood.
Nutrition literacy sessions – Food safety during neutropenia, protein targets, fluids; empowers safer eating (details below).
Falls-prevention walk-through at home – Remove loose rugs, improve lighting, add grab bars; reduces injury risk if platelets are low.
Infection-control coaching – Hand hygiene, masking in crowds, safe pet care, plant/soil precautions.
Medication-side-effect tracker – Early reporting of mouth sores, rashes, diarrhea, or bruising helps the team adjust therapy promptly.
Care-partner training – Simple transfer assist, fever watch, when to call; lowers ER visits.

Drug Treatments

Doses and schedules vary by age, kidney/liver function, genetic markers, and trial protocols. What follows are typical labels/standards—your oncology team personalizes them.

“7+3” Induction (cytarabine + anthracycline)
Class: Antimetabolite + anthracycline.
Typical dose/time: Cytarabine 100–200 mg/m²/day by continuous IV on Days 1–7; daunorubicin 60 mg/m² IV (or idarubicin 12 mg/m²) on Days 1–3.
Purpose: Rapidly clear blasts to reach complete remission (CR).
Mechanism: Cytarabine blocks DNA synthesis; anthracyclines intercalate DNA/topoisomerase-II inhibition.
Key side effects: Low blood counts, mucositis, hair loss; anthracycline cardiotoxicity risk.
CPX-351 (daunorubicin/cytarabine liposome, Vyxeos)
Class: Fixed-ratio liposomal combo.
Use: Newly diagnosed therapy-related AML or AML with myelodysplasia-related changes.
Dose: Induction on Days 1, 3, 5; consolidation on Days 1, 3 (per label).
Why: Improves outcomes in these high-risk categories vs. conventional 7+3 in trials.
Notes: Similar side effects to intensive chemo; prolonged cytopenias common.
Midostaurin (Rydapt)
Class: Multikinase/FLT3 inhibitor.
Use: Newly diagnosed FLT3-mutated AML with standard 7+3 induction and HiDAC consolidation.
Dose: 50 mg orally twice daily on Days 8–21 of induction and consolidation.
Mechanism: Inhibits FLT3 signaling to reduce leukemic cell growth.
Side effects: Nausea, cytopenias, rash; not used as single-agent induction.
Quizartinib (Vanflyta)
Class: FLT3-ITD selective inhibitor.
Use: With induction/consolidation and as maintenance in newly diagnosed FLT3-ITD-positive AML.
Dose: Per label (tablets; maintenance doses may be 26.5–53 mg depending on QTc).
Notes: Avoid with significant QT prolongation; part of upfront therapy since 2023 FDA approval.
Gilteritinib (Xospata)
Class: FLT3 inhibitor.
Use: Relapsed/refractory FLT3-mutated AML.
Dose: 120 mg orally once daily until progression/toxicity.
Notes: Watch for differentiation syndrome, QT prolongation, and liver tests.
Venetoclax (Venclexta) + HMA/LDAC
Class: BCL-2 inhibitor.
Use: Newly diagnosed adults ≥75 years or unfit for intensive chemo, combined with azacitidine, decitabine, or low-dose cytarabine.
Dose: Ramp-up to target dose; combinations are 28-day cycles.
Notes: Tumor lysis syndrome precautions; deep remissions common in older/unfit patients.
Azacitidine (injectable) or Decitabine (HMAs)
Class: Hypomethylating agents.
Use: Lower-intensity therapy; often paired with venetoclax in unfit patients.
Dose: Azacitidine 75 mg/m² SC/IV Days 1–7 q28d; decitabine 20 mg/m² IV Days 1–5 q28d (typical).
Notes: Gradual responses; monitor counts and infections.
Oral azacitidine (Onureg) maintenance
Class: HMA (oral, different formulation/indication than injectable).
Use: Maintenance for adults in first CR/CRi after intensive induction who are not transplant candidates.
Dose: 300 mg orally once daily on Days 1–14 of 28-day cycles.
Benefit: Prolongs overall survival in QUAZAR AML-001.
Gemtuzumab ozogamicin (Mylotarg)
Class: CD33-targeted antibody-drug conjugate.
Use: In CD33-positive AML, as single-agent in R/R disease or added to induction in select newly diagnosed patients (esp. core-binding-factor AML).
Dose: 3 mg/m² on defined days with chemo per label.
Watch: VOD risk (liver), infusion reactions, cytopenias.
Glasdegib (Daurismo) + low-dose cytarabine
Class: Hedgehog pathway inhibitor.
Use: Newly diagnosed adults ≥75 years or unfit for intensive therapy.
Dose: 100 mg orally daily + LDAC schedule in 28-day cycles.
Notes: Monitor for QT prolongation, renal/hepatic cautions.
IDH1 inhibitor — Ivosidenib (Tibsovo)
Use: R/R IDH1-mutated AML; also used in some frontline combinations by protocol.
Dose: 500 mg orally daily.
Watch: Differentiation syndrome, QT prolongation, liver tests.
IDH2 inhibitor — Enasidenib (Idhifa)
Use: R/R IDH2-mutated AML.
Dose: 100 mg orally daily.
Notes: Differentiation syndrome management with steroids and monitoring.
IDH1 inhibitor — Olutasidenib (Rezlidhia)
Use: R/R IDH1-mutated AML.
Dose: 150 mg orally twice daily (label).
Notes: Watch for differentiation syndrome; drug–drug interactions.
High-dose cytarabine (HiDAC) consolidation
Class: Antimetabolite.
Use: Post-remission cycles after 7+3 (younger/fit patients).
Dose: Often 3 g/m² IV over 3 h q12h on Days 1, 3, 5 × up to 3–4 cycles.
Notes: Cerebellar toxicity and ocular prophylaxis (steroid eye drops).
APL-specific: ATRA + arsenic trioxide
Use: Standard-/low-risk APL without routine chemo; high-risk adds limited chemo or GO.
Mechanism: Forces leukemic promyelocytes to mature and die.
Notes: Early coagulopathy support is life-saving; watch differentiation syndrome (steroids).

Dietary “Molecular” Supports

Food safety during neutropenia is crucial: wash hands, cook meats/eggs fully, avoid raw sprouts/sushi/unpasteurized dairy, rinse produce well, and use separate cutting boards. (Your team may tailor advice; “strict neutropenic diets” are less emphasized than safe-food handling.)

Adequate protein (1.2–1.5 g/kg/day unless contraindicated) — supports immune proteins and healing; spread across meals/snacks.
Vitamin D (check level; often 800–2000 IU/day if low) — immune modulation and bone health; avoid megadoses without labs.
Omega-3s (EPA/DHA 1–2 g/day with food) — may help inflammation, appetite, and triglycerides; hold if bleeding risk is high.
Glutamine (e.g., 10 g 2–3×/day short-term) — sometimes used for mucositis support; discuss with your team.
Zinc (e.g., 10–25 mg/day, short course) — for taste changes and wound healing; long-term excess can lower copper.
Vitamin B12 & folate (only if deficient) — needed for RBC formation; avoid high “methyl” doses without medical advice.
Selenium (50–100 mcg/day) — antioxidant selenoproteins; avoid excess.
Magnesium (as needed) — chemo and amphotericin can lower Mg; correct deficiency to reduce cramps/arrhythmias.
Electrolyte-rich fluids — support hydration through fevers/diarrhea; pick low-sugar options if glucose is an issue.
Medical nutrition shakes — calorie/protein support during poor appetite; choose pasteurized products.
(These are supportive only; some supplements interact with chemo. Always clear with your oncologist/pharmacist.)

Immunity/Regenerative/Stem-Cell–Related” Medicines

Filgrastim (G-CSF) — boosts neutrophil production to shorten neutropenia after chemo; typical daily injections until count recovery (use is individualized in AML).
Pegfilgrastim — longer-acting G-CSF, single dose per cycle in some settings; not used during intensive induction in all centers—team discretion.
Sargramostim (GM-CSF) — may be used after induction/transplant to speed myeloid recovery.
Epoetin alfa / Darbepoetin — for chemo-related anemia when transfusion avoidance is the goal; not used if curative therapy may be compromised; iron status matters.
IVIG (immunoglobulin), selected cases — for recurrent, severe infections with documented hypogammaglobulinemia.
TPO-receptor agonists (eltrombopag/romiplostim) — not routine in AML; occasionally considered off-label for severe chemotherapy-related thrombocytopenia under specialist oversight.
Growth-factor and prophylaxis strategies follow infectious-disease/oncology guidelines and are tailored to your risk profile.

Common Procedures/“Surgeries

Central venous catheter/port placement — reliable access for chemo, transfusions, and labs; reduces repeated needle sticks.
Leukapheresis (emergency) — short-term removal of excess blasts from blood to reduce “leukostasis” symptoms before chemo starts.
Lumbar puncture ± intrathecal therapy — to check/treat CNS involvement if symptoms/risk; APL and monocytic subtypes may be assessed per protocol.
Allogeneic hematopoietic stem-cell transplant (HSCT) — replaces diseased marrow with donor cells after conditioning; used for cure in many intermediate/high-risk patients.
Splenectomy (rare) — considered only for severe, symptomatic splenomegaly with hypersplenism not controlled otherwise.

Prevention & Safety Tips

Hand hygiene: soap/water 20 s or sanitizer before meals and after bathroom.
Food safety: no raw eggs/fish/unpasteurized dairy; wash produce; separate cutting boards.
Fever plan: check temperature if you feel unwell; call urgently for ≥38.0 °C.
Mask in crowds, avoid sick contacts during profound neutropenia.
Oral care: soft brush, bland rinses; report mouth sores early.
Skin care: moisturize, treat cracks; report rashes.
Bleeding safety: soft toothbrush, electric razor; avoid high-risk sports when platelets are low.
Vaccine timing: inactivated vaccines may be scheduled between cycles; avoid live vaccines during immunosuppression.
Medicines list: keep up-to-date list; clear all OTC/herbals.
Home safety: fall-proofing, good lighting, shower chair if weak.

When to See (or Call) Your Doctor Urgently

Fever ≥38.0 °C, chills, or rigors.
New bleeding (nose/gums), black stools, red urine, or unexplained bruises.
Shortness of breath, chest pain, severe headache, confusion, weakness on one side.
Fast swelling, sudden weight gain, or shortness of breath on IDH/FLT3 therapies (possible differentiation syndrome).

What to Eat and What to Avoid

Eat: Well-cooked proteins (eggs, fish, chicken), beans/lentils, cooked grains, pasteurized dairy, well-washed and preferably cooked vegetables, peeled fruits, nuts from sealed packs, and plenty of safe fluids.
Avoid (during neutropenia): Raw or undercooked meats/seafood/eggs; unpasteurized milk/juice; salad-bar or buffet foods; raw sprouts; mold-ripened cheeses; foods past “use-by” dates.
Everyday tips: Small, frequent meals; protein at each meal; carry hand sanitizer; when in doubt—cook it, peel it, or leave it.

Frequently Asked Questions

Is FAB still used?
Yes—mainly for description (M0–M7). Treatment decisions now lean heavily on gene findings (WHO/ICC), but FAB terms are still common in reports.
Why is APL (M3) treated differently?
Because APL cells respond to ATRA and ATO, which force them to mature; this can cure many patients with less traditional chemo.
What does “7+3” mean?
Seven days of continuous cytarabine plus three days of an anthracycline; it’s the standard backbone for fit patients.
What if I’m older or not fit for intensive chemo?
Doctors often use venetoclax with azacitidine/decitabine or low-dose cytarabine, or glasdegib+LDAC.
What are FLT3 inhibitors and who gets them?
If your leukemia has an FLT3 mutation, midostaurin is added to initial chemo; gilteritinib treats relapsed disease; quizartinib is approved with upfront chemo for FLT3-ITD.
What are IDH inhibitors?
If you have IDH1 or IDH2 mutations, ivosidenib/olutasidenib (IDH1) or enasidenib (IDH2) may be used, often in relapsed settings.
Why might I receive gemtuzumab ozogamicin?
In CD33-positive AML (especially core-binding-factor AML), adding it to induction can lower relapse risk; it’s also used in some relapsed cases.
What is “maintenance” with oral azacitidine?
If you reach CR after intensive chemo but cannot proceed to transplant, oral azacitidine can extend survival.
Will I need a transplant?
Depends on your genetic risk and response. Many intermediate/high-risk cases go to allogeneic HSCT in first CR.
How are infections prevented?
Careful hygiene, food safety, prompt fever reporting, and sometimes antibacterial/antifungal prophylaxis based on IDSA/ASCO guidance.
Are growth factors (G-CSF) routine?
They can shorten neutropenia but are used selectively during AML therapy; policies vary by center and phase.
Can I exercise during treatment?
Yes—light, count-aware activity under PT guidance improves function and mood. Stop for fever, bleeding, chest pain, or dizziness.
What diet is safest?
Focus on safe handling and cooked foods during low-count periods; hydrate well and aim for steady protein intake.
What side effects should I report immediately on targeted drugs?
Sudden shortness of breath, edema, weight gain, fevers, or low blood pressure—possible differentiation syndrome—need urgent attention.
What does remission mean?
No detectable leukemia by standard tests (CR). Consolidation and sometimes maintenance or transplant are still needed to keep AML away.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 07, 2025.

PDF Documents For This Disease Condition

References

SaveSavedRemoved 0